This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Szekanecz, Z Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Szekanecz, Z Articles by Shoenfeld, Y Social Bookmarking                         What's this?

Lupus and cardiovascular disease: the facts

Third Department of Medicine, Rheumatology Division, University Medical School of Debrecen, Debrecen, Hungary, szekanecz{at}iiibel.dote.hu

Y Shoenfeld

Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

Accelerated atherosclerosis leading to coronary artery disease (CAD) and other cardiac manifestations have increasing importance for the management and outcome of systemic lupus erythematosus (SLE). There is increased cardiovascular mortality in SLE. Several traditional and disease-related risk factors, as well as corticosteroids are involved in lupus-associated atherosclerosis and its clinical manifestations. Cardiovascular risk is even higher in lupus patients also having secondary antiphospholipid syndrome (APS) due to the additive effects of SLE- and APS-related risk factors. The primary and secondary prevention of atherosclerosis and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications. Apart from CAD, other cardiac manifestations may also be present in SLE patients. Among these conditions, pericarditis is the most common, however, myocarditis, endocarditis and valvular disease, conduction abnormalities, impairment of systolic and diastolic function, pulmonary or peripheral arterial hypertension and microcirculatory problems may also occur. Early diagnosis of SLE, active immunosuppressive treatment and close follow-up of lupus patients and prevention may help to minimize cardiovascular risk in these individuals.

Key Words: systemic lupus erythematosus • atherosclerosis • cardiovascular disease • cardiac manifestations

Lupus, Vol. 15, No. 11 suppl, 3-10 (2006)
DOI: 10.1177/0961203306071665


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Apte, G. McGwin Jr, L. M. Vila, R. A. Kaslow, G. S. Alarcon, J. D. Reveille, and for the LUMINA Study Group Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort Rheumatology, March 1, 2008; 47(3): 362 - 367. [Abstract] [Full Text] [PDF]